Literature DB >> 24076665

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.

Mariella Gruber Filbin1, Sukriti K Dabral, Maria F Pazyra-Murphy, Shakti Ramkissoon, Andrew L Kung, Ekaterina Pak, Jarom Chung, Matthew A Theisen, Yanping Sun, Yoko Franchetti, Yu Sun, David S Shulman, Navid Redjal, Barbara Tabak, Rameen Beroukhim, Qi Wang, Jean Zhao, Marion Dorsch, Silvia Buonamici, Keith L Ligon, Joseph F Kelleher, Rosalind A Segal.   

Abstract

In glioblastoma, phosphatidylinositol 3-kinase (PI3K) signaling is frequently activated by loss of the tumor suppressor phosphatase and tensin homolog (PTEN). However, it is not known whether inhibiting PI3K represents a selective and effective approach for treatment. We interrogated large databases and found that sonic hedgehog (SHH) signaling is activated in PTEN-deficient glioblastoma. We demonstrate that the SHH and PI3K pathways synergize to promote tumor growth and viability in human PTEN-deficient glioblastomas. A combination of PI3K and SHH signaling inhibitors not only suppressed the activation of both pathways but also abrogated S6 kinase (S6K) signaling. Accordingly, targeting both pathways simultaneously resulted in mitotic catastrophe and tumor apoptosis and markedly reduced the growth of PTEN-deficient glioblastomas in vitro and in vivo. The drugs tested here appear to be safe in humans; therefore, this combination may provide a new targeted treatment for glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24076665      PMCID: PMC3923315          DOI: 10.1038/nm.3328

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  39 in total

1.  New developments in the discovery of small molecule Hedgehog pathway antagonists.

Authors:  Martin R Tremblay; Karen McGovern; Margaret A Read; Alfredo C Castro
Journal:  Curr Opin Chem Biol       Date:  2010-06       Impact factor: 8.822

Review 2.  Death through a tragedy: mitotic catastrophe.

Authors:  H Vakifahmetoglu; M Olsson; B Zhivotovsky
Journal:  Cell Death Differ       Date:  2008-04-11       Impact factor: 15.828

3.  Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

Authors:  Shifeng Pan; Xu Wu; Jiqing Jiang; Wenqi Gao; Yongqin Wan; Dai Cheng; Dong Han; Jun Liu; Nathan P Englund; Yan Wang; Stefan Peukert; Karen Miller-Moslin; Jing Yuan; Ribo Guo; Melissa Matsumoto; Anthony Vattay; Yun Jiang; Jeffrey Tsao; Fangxian Sun; AnneMarie C Pferdekamper; Stephanie Dodd; Tove Tuntland; Wieslawa Maniara; Joseph F Kelleher; Yung-Mae Yao; Markus Warmuth; Juliet Williams; Marion Dorsch
Journal:  ACS Med Chem Lett       Date:  2010-03-16       Impact factor: 4.345

4.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

5.  Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.

Authors:  Antony Hsieh; Ron Ellsworth; David Hsieh
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

Review 6.  Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy.

Authors:  Monica Venere; Howard A Fine; Peter B Dirks; Jeremy N Rich
Journal:  Glia       Date:  2011-05-05       Impact factor: 7.452

7.  Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas.

Authors:  Qijin Xu; Xiangpeng Yuan; Gentao Liu; Keith L Black; John S Yu
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

Review 8.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

9.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR.

Authors:  Ajay Pandita; Kenneth D Aldape; Gelareh Zadeh; Abhijit Guha; C David James
Journal:  Genes Chromosomes Cancer       Date:  2004-01       Impact factor: 5.006

10.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Authors:  Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

View more
  77 in total

1.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

2.  Effects of NOTCH1 signaling inhibitor γ-secretase inhibitor II on growth of cancer stem cells.

Authors:  Xiaodong Ding; Changqing Ding; Fei Wang; Wenshuai Deng; Mingming Yu; Qinghai Meng; Peng Sun
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

Review 3.  Unraveling the therapeutic potential of the Hedgehog pathway in cancer.

Authors:  Dereck Amakye; Zainab Jagani; Marion Dorsch
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

4.  Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Authors:  Patrick Y Wen; Mehdi Touat; Brian M Alexander; Ingo K Mellinghoff; Shakti Ramkissoon; Christine S McCluskey; Kristine Pelton; Sam Haidar; Sankha S Basu; Sarah C Gaffey; Loreal E Brown; Juan Emmanuel Martinez-Ledesma; Shaofang Wu; Jungwoo Kim; Wei Wei; Mi-Ae Park; Jason T Huse; John G Kuhn; Mikael L Rinne; Howard Colman; Nathalie Y R Agar; Antonio M Omuro; Lisa M DeAngelis; Mark R Gilbert; John F de Groot; Timothy F Cloughesy; Andrew S Chi; Thomas M Roberts; Jean J Zhao; Eudocia Q Lee; Lakshmi Nayak; James R Heath; Laura L Horky; Tracy T Batchelor; Rameen Beroukhim; Susan M Chang; Azra H Ligon; Ian F Dunn; Dimpy Koul; Geoffrey S Young; Michael D Prados; David A Reardon; W K Alfred Yung; Keith L Ligon
Journal:  J Clin Oncol       Date:  2019-02-04       Impact factor: 44.544

Review 5.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Authors:  Naoko Takebe; Lucio Miele; Pamela Jo Harris; Woondong Jeong; Hideaki Bando; Michael Kahn; Sherry X Yang; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 6.  Sonic hedgehog signaling in the postnatal brain.

Authors:  Arturo Álvarez-Buylla; Rebecca A Ihrie
Journal:  Semin Cell Dev Biol       Date:  2014-05-23       Impact factor: 7.727

7.  Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.

Authors:  Hongqi Liu; Xizhi Feng; Kelli N Ennis; Catherine A Behrmann; Pranjal Sarma; Tony T Jiang; Satoshi Kofuji; Liang Niu; Yiwen Stratton; Hala Elnakat Thomas; Sang-Oh Yoon; Atsuo T Sasaki; David R Plas
Journal:  Cell Rep       Date:  2017-02-28       Impact factor: 9.423

8.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Authors:  Wolfgang Wick; Susan Dettmer; Anne Berberich; Tobias Kessler; Irini Karapanagiotou-Schenkel; Antje Wick; Frank Winkler; Elke Pfaff; Benedikt Brors; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; Andreas Eisenmenger; Andreas von Deimling; David T W Jones; Stefan M Pfister; Felix Sahm; Michael Platten
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

9.  Smoothened antagonist GDC-0449 (Vismodegib) inhibits proliferation and triggers apoptosis in colon cancer cell lines.

Authors:  Chuanqing Wu; Shaobo Hu; Ji Cheng; Guobin Wang; Kaixiong Tao
Journal:  Exp Ther Med       Date:  2017-03-29       Impact factor: 2.447

Review 10.  Molecular and genetic pathways in gliomas: the future of personalized therapeutics.

Authors:  Ryan Grant; Luis Kolb; Jennifer Moliterno
Journal:  CNS Oncol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.